Previous 10 | Next 10 |
NEWARK, Calif. , Aug. 6, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today reported financial results for the second quarter ended June 30, 2020 , and provided an update on clinical development programs. "We have succeeded in bringing three differentiated ca...
Protagonist Therapeutics ( PTGX ) is a biotech that should be on your radar after its latest trial update. This involves the release of positive phase 2 data using its drug PTG-300 to treat patients with polycythemia vera. What made the data positive is that all 6 patients that were treate...
NEWARK, Calif. , June 17, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for PTG-300 for the treatment of polycythemia vera. PTG-300 is an injectable synthetic peptide ...
NEWARK, Calif. , June 16, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel , Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the upcoming virtual BMO Prescriptions for Success Healthcare Conference...
Protagonist Therapeutics (PTGX) is a relatively unknown biotech company focused on the development of novel peptide drugs. The company has recently shown exciting data for their hepcidin mimetic drug PTG-300 in Polycythemia Vera ("PV") which resulted in a doubling of their share price. In this...
NEWARK, Calif. , June 4, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the company will present data from its Phase 2 trial of PTG-300 for the treatment of beta-thalassemia at the 25 th European Hematology Association (EHA) Annual Congress, which ...
CARMIEL, Israel , May 28, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx ®...
Protagonist Therapeutics, Inc. (PTGX) Q1 2020 Results Conference Call May 7, 2020 5:00 PM ET Company Participants Don Kalkofen - Chief Financial Officer Dinesh Patel - President and Chief Executive Officer Samuel Saks - Chief Medical Officer Ronald Hoffman - M.D., Director of t...
Protagonist Therapeutics (NASDAQ: PTGX ) prices upsized public offering of 7M common shares (from 5M shares) at $14.00 per share yielding gross proceeds of $98M. More news on: Protagonist Therapeutics, Inc., Healthcare stocks news, , Read more ...
NEWARK, Calif. , May 12, 2020 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq: PTGX), a clinical stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 7,000,000 shares of its common stock at a price to the public of...
News, Short Squeeze, Breakout and More Instantly...
Protagonist Therapeutics Inc. Company Name:
PTGX Stock Symbol:
NASDAQ Market:
Protagonist Therapeutics Inc. Website:
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
NEWARK, CA / ACCESSWIRE / August 1, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced publication of preclinical and phase 1 clinical data on JNJ-2113 in the journal Scientific Reports , a Nature publication and the 5th most-cited journal in the world, acc...
Dr. Yeilding joins Protagonist from Janssen Pharmaceutical Companies of Johnson & Johnson, where he held leadership roles in the immunology therapeutic area, bringing extensive experience in R&D and commercialization of novel therapeutics in the I&I space NEWARK, CA / ACCESSWIRE /...